| scholarly article | Q13442814 |
| P50 | author | Rafael Roesler | Q77616037 |
| P2093 | author name string | Algemir Lunardi Brunetto | |
| Michel Pinheiro Dos Santos | |||
| Caroline Brunetto de Farias | |||
| Lauro José Gregianin | |||
| André Tesainer Brunetto | |||
| Bárbara Kunzler Souza | |||
| Ricardo Gehrke Becker | |||
| Tiago Elias Heinen | |||
| Patrícia Luciana da Costa Lopez | |||
| Rafael Pereira Dos Santos | |||
| Amanda da Rocha | |||
| Luís Fernando da Rosa Rivero | |||
| Marco Aurélio Silva Filho | |||
| P2860 | cites work | Neurotrophins: roles in neuronal development and function | Q24656166 |
| Gastrin releasing peptide and gastrin releasing peptide receptor expression in gastrointestinal carcinoid tumours | Q24672702 | ||
| Neurotrophin-regulated signalling pathways | Q24678332 | ||
| Understanding the Biology of Bone Sarcoma from Early Initiating Events through Late Events in Metastasis and Disease Progression | Q26829949 | ||
| Characterization and drug resistance patterns of Ewing's sarcoma family tumor cell lines | Q28535586 | ||
| Changes in incidence and survival of Ewing sarcoma patients over the past 3 decades: Surveillance Epidemiology and End Results data. | Q31157886 | ||
| Expression of the neurotrophin receptor TrkB is associated with unfavorable outcome in Wilms' tumor | Q31826551 | ||
| Short-term striatal gene expression responses to brain-derived neurotrophic factor are dependent on MEK and ERK activation | Q33434423 | ||
| CD133 expression in chemo-resistant Ewing sarcoma cells | Q33546702 | ||
| Modeling initiation of Ewing sarcoma in human neural crest cells | Q33894979 | ||
| Mesenchymal stem cell features of Ewing tumors | Q34003979 | ||
| Long-term survivors of childhood Ewing sarcoma: report from the childhood cancer survivor study | Q34169663 | ||
| BDNF/TrkB signaling protects HT-29 human colon cancer cells from EGFR inhibition. | Q34290956 | ||
| A Ewing's sarcoma cell line showing some, but not all, of the traits of a cholinergic neuron | Q34314539 | ||
| Neurotrophin signaling: many exciting surprises! | Q34525867 | ||
| miR-34a predicts survival of Ewing's sarcoma patients and directly influences cell chemo-sensitivity and malignancy | Q39465507 | ||
| The histone deacetylase inhibitor sodium butyrate in combination with brain-derived neurotrophic factor reduces the viability of DAOY human medulloblastoma cells. | Q39544836 | ||
| BDNF/TrkB content and interaction with gastrin-releasing peptide receptor blockade in colorectal cancer | Q39562114 | ||
| Gastrin-releasing peptide receptors regulate proliferation of C6 Glioma cells through a phosphatidylinositol 3-kinase-dependent mechanism | Q39983166 | ||
| Microarray analysis reveals differential gene expression patterns and regulation of single target genes contributing to the opposing phenotype of TrkA- and TrkB-expressing neuroblastomas. | Q40473835 | ||
| DNA microarrays reveal relationship of Ewing family tumors to both endothelial and fetal neural crest-derived cells and define novel targets | Q40490707 | ||
| Fibroblast growth factor 2 induces differentiation and apoptosis of Askin tumour cells. | Q40604282 | ||
| Activation of trkA induces differentiation and inhibits the growth of JK-GMS Askin tumor cells | Q40750316 | ||
| Class III β-tubulin expression in advanced-stage serous ovarian carcinoma effusions is associated with poor survival and primary chemoresistance | Q43454152 | ||
| Brain-derived neurotrophic factor activation of TrkB protects neuroblastoma cells from chemotherapy-induced apoptosis via phosphatidylinositol 3'-kinase pathway. | Q44220786 | ||
| Addition of ifosfamide and etoposide to standard chemotherapy for Ewing's sarcoma and primitive neuroectodermal tumor of bone | Q44320806 | ||
| BDNF/TrkB signaling as an anti-tumor target | Q48840378 | ||
| Absence of detectable EWS/FLI1 expression after therapy-induced neural differentiation in Ewing sarcoma. | Q51996116 | ||
| Induction of cell death by basic fibroblast growth factor in Ewing's sarcoma. | Q52162635 | ||
| EWS-FLI-1 expression triggers a Ewing's sarcoma initiation program in primary human mesenchymal stem cells. | Q53487773 | ||
| Functional receptors for nerve growth factor on Ewing's sarcoma and Wilm's tumor cells | Q69356002 | ||
| Activation of TRK genes in Ewing's sarcoma. Trk A receptor expression linked to neural differentiation | Q73063429 | ||
| Neurogenic potential of Ewing's sarcoma cells | Q73082881 | ||
| Coexpression of mRNA for the full-length neurotrophin receptor trk-C and trk-A in favourable neuroblastoma | Q74526320 | ||
| Ewing's sarcoma | Q82884131 | ||
| K252a is a selective inhibitor of the tyrosine protein kinase activity of the trk family of oncogenes and neurotrophin receptors | Q34537348 | ||
| Phase I trial of lestaurtinib for children with refractory neuroblastoma: a new approaches to neuroblastoma therapy consortium study | Q34549193 | ||
| A phase 2 trial of the FLT3 inhibitor lestaurtinib (CEP701) as first-line treatment for older patients with acute myeloid leukemia not considered fit for intensive chemotherapy | Q34549807 | ||
| K-252 compounds, novel and potent inhibitors of protein kinase C and cyclic nucleotide-dependent protein kinases | Q34684562 | ||
| Upregulation of TrkB promotes epithelial-mesenchymal transition and anoikis resistance in endometrial carcinoma | Q34923263 | ||
| Class III β‐tubulin in human development and cancer | Q35125146 | ||
| Roles of trk family neurotrophin receptors in medullary thyroid carcinoma development and progression | Q35131575 | ||
| The role of AXL and the in vitro activity of the receptor tyrosine kinase inhibitor BGB324 in Ewing sarcoma | Q35149569 | ||
| Blockage of tropomyosin receptor kinase a (TrkA) enhances chemo-sensitivity in breast cancer cells and inhibits metastasis in vivo | Q35173551 | ||
| NGF-induced TrkA/CD44 association is involved in tumor aggressiveness and resistance to lestaurtinib | Q35833152 | ||
| Immunohistochemical localization of Trk receptor protein in pediatric small round blue cell tumors. | Q35833678 | ||
| Experimental evidence for a neural origin of Ewing's sarcoma of bone | Q35856430 | ||
| Expression of mRNA for the neurotrophin receptor trkC in neuroblastomas with favourable tumour stage and good prognosis | Q36136048 | ||
| Trk inhibitor attenuates the BDNF/TrkB-induced protection of neuroblastoma cells from etoposide in vitro and in vivo | Q36214947 | ||
| Inducible expression of chimeric EWS/ETS proteins confers Ewing's family tumor-like phenotypes to human mesenchymal progenitor cells | Q36498079 | ||
| The biology of ewing sarcoma | Q36546372 | ||
| NTRK1 rearrangement in colorectal cancer patients: evidence for actionable target using patient-derived tumor cell line | Q36629492 | ||
| Expression and function of TRK-B and BDNF in human neuroblastomas | Q36644617 | ||
| Dose-intensified compared with standard chemotherapy for nonmetastatic Ewing sarcoma family of tumors: a Children's Oncology Group Study. | Q37198992 | ||
| Ewing's sarcoma: overcoming the therapeutic plateau | Q37487126 | ||
| On Trk--the TrkB signal transduction pathway is an increasingly important target in cancer biology | Q37597739 | ||
| Influence of GRPR and BDNF/TrkB signaling on the viability of breast and gynecologic cancer cells | Q37641064 | ||
| Sarcomas gone bad: what to do about recurrent Ewing sarcoma | Q37890995 | ||
| Association between class III β-tubulin expression and response to paclitaxel/vinorebine-based chemotherapy for non-small cell lung cancer: a meta-analysis | Q37981433 | ||
| The neurotrophin family of neurotrophic factors: an overview | Q37988419 | ||
| Innovative therapies in Ewing Sarcoma | Q38169514 | ||
| Therapy resistance mechanisms in Ewing's sarcoma family tumors | Q38182423 | ||
| High levels of class III β-tubulin expression are associated with aggressive tumor features in breast cancer | Q38719315 | ||
| TrkB inhibition by GNF-4256 slows growth and enhances chemotherapeutic efficacy in neuroblastoma xenografts | Q38940598 | ||
| In vitro antitumor effect of sodium butyrate and zoledronic acid combined with traditional chemotherapeutic drugs: a paradigm of synergistic molecular targeting in the treatment of Ewing sarcoma. | Q39045925 | ||
| Acquired resistance to EGFR inhibitors is associated with a manifestation of stem cell-like properties in cancer cells. | Q39173405 | ||
| Identification of common and distinctive mechanisms of resistance to different anti-IGF-IR agents in Ewing's sarcoma. | Q39314094 | ||
| AZ64 inhibits TrkB and enhances the efficacy of chemotherapy and local radiation in neuroblastoma xenografts | Q39343234 | ||
| Neuronal differentiation by analogs of staurosporine | Q39367820 | ||
| P4510 | describes a project that uses | ImageJ | Q1659584 |
| ImageQuant | Q112270642 | ||
| P433 | issue | 23 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | chemotherapy | Q974135 |
| P304 | page(s) | 34860-34880 | |
| P577 | publication date | 2016-06-01 | |
| P1433 | published in | Oncotarget | Q1573155 |
| P1476 | title | Trk inhibition reduces cell proliferation and potentiates the effects of chemotherapeutic agents in Ewing sarcoma | |
| P478 | volume | 7 |
| Q91811059 | Antitumor Activities and Cellular Changes Induced by TrkB Inhibition in Medulloblastoma |
| Q51334063 | Combined Treatments with a Retinoid Receptor Agonist and Epigenetic Modulators in Human Neuroblastoma Cells. |
| Q41912578 | Dual inhibition of BDNF/TrkB and autophagy: a promising therapeutic approach for colorectal cancer |
| Q54974651 | Gene expression changes associated with chemotherapy resistance in Ewing sarcoma cells. |
| Q50201584 | Neurotrophin Trk Receptors: New Targets for Cancer Therapy |
| Q48110212 | Targeting Histone Deacetylase Activity to Arrest Cell Growth and Promote Neural Differentiation in Ewing Sarcoma. |
| Q61456294 | Targeting the BDNF/TrkB pathway for the treatment of tumors |
| Q54941876 | Targeting tyrosine receptor kinase B in gliomas. |
| Q38666650 | Uncovering the role of brain-derived neurotrophic factor/tyrosine kinase receptor B signaling in head and neck malignancies. |
Search more.